- Report
- August 2024
- 200 Pages
Global
From €2177EUR$2,290USD£1,829GBP
- Report
- September 2024
- 135 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- October 2024
- 185 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 197 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 199 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- October 2024
- 190 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- December 2024
- 100 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- March 2025
- 94 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 175 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- March 2025
- 258 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Clinical Trials
- November 2024
- 450 Pages
Global
From €4753EUR$5,000USD£3,993GBP
- Drug Pipelines
- April 2024
- 220 Pages
Global
From €2852EUR$3,000USD£2,396GBP
- Report
- December 2024
- 144 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Drug Pipelines
- November 2024
- 240 Pages
Global
From €2852EUR$3,000USD£2,396GBP
- Report
- April 2024
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- October 2024
- 200 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Report
- April 2024
- 187 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- December 2024
- 144 Pages
Global
From €14255EUR$14,995USD£11,976GBP
- Report
- August 2024
- 268 Pages
Global
From €3422EUR$3,600USD£2,875GBP

Rapid Acting Insulin is a type of insulin used to treat endocrine and metabolic disorders. It is a short-acting insulin that is injected before meals to help control blood sugar levels. It works quickly to lower blood sugar levels and can be used in combination with other types of insulin. Rapid Acting Insulin is typically used to treat type 1 diabetes, but can also be used to treat type 2 diabetes. It is important to monitor blood sugar levels closely when using Rapid Acting Insulin, as it can cause hypoglycemia if taken in too high of a dose.
Rapid Acting Insulin is available in both injectable and inhaled forms. Injectable forms include regular insulin, lispro, aspart, and glulisine. Inhaled forms include Afrezza and Admelog. These forms of insulin are designed to work quickly and provide a more convenient way to manage blood sugar levels.
Some companies in the Rapid Acting Insulin market include Eli Lilly, Novo Nordisk, Sanofi, and Merck. These companies produce a variety of Rapid Acting Insulin products, including injectable and inhaled forms. Show Less Read more